Twice-weekly teriparatide improves lumbar spine BMD independent of pre-treatment BMD and bone turnover marker levels

[1] Sugimoto T(2017)24-month open-label teriparatide once-weekly efficacy research trial examining bone mineral density in subjects with primary osteoporosis and high fracture risk Adv Ther 34 1727-1740

[2] Shiraki M(2012)Randomized teriparatide [human parathyroid hormone (PTH) 1–34] once-weekly efficacy research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk J Clin Endocrinol Metab 97 3097-3106

[3] Fukunaga M(2018)Persistence of and switches from teriparatide treatment among women and men with osteoporosis in the real world: a claims database analysis Arch Osteoporos 13 54-2331

[4] Hagino H(2019)Study of twice-weekly injections of Teriparatide by comparing efficacy with once-weekly injections in osteoporosis patients: the TWICE study Osteoporos Int 30 2321-56

[5] Sone T(2019)Impact of patient background factors on the treatment efficacy of once-weekly teriparatide Osteoporos Sarcopenia 5 51-257

[6] Nakano T(2013)Diagnostic criteria for primary osteoporosis: year 2012 revision J Bone Miner Metab 31 247-e264

[7] Kishimoto H(2020)Bone mineral density after transitioning from denosumab to alendronate J Clin Endocrinol Metab 105 e255-446

[8] Ito M(2014)Once-weekly teriparatide reduces the risk of vertebral fracture in patients with various fracture risks: subgroup analysis of the Teriparatide Once-Weekly Efficacy Research (TOWER) trial J Bone Miner Metab 32 441-140

[9] Yoshikawa H(2019)Bone mineral density response rates are greater in patients treated with abaloparatide compared with those treated with placebo or teriparatide: results from the ACTIVE phase 3 trial Bone 120 137-312

[10] Kishida M(2012)Responder analysis of the effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer Prostate Cancer Prostatic Dis 15 308-205

[1] Sugimoto T(2017)24-month open-label teriparatide once-weekly efficacy research trial examining bone mineral density in subjects with primary osteoporosis and high fracture risk Adv Ther 34 1727-1740

[2] Shiraki M(2012)Randomized teriparatide [human parathyroid hormone (PTH) 1–34] once-weekly efficacy research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk J Clin Endocrinol Metab 97 3097-3106

[3] Fukunaga M(2018)Persistence of and switches from teriparatide treatment among women and men with osteoporosis in the real world: a claims database analysis Arch Osteoporos 13 54-2331

[4] Hagino H(2019)Study of twice-weekly injections of Teriparatide by comparing efficacy with once-weekly injections in osteoporosis patients: the TWICE study Osteoporos Int 30 2321-56

[5] Sone T(2019)Impact of patient background factors on the treatment efficacy of once-weekly teriparatide Osteoporos Sarcopenia 5 51-257

[6] Nakano T(2013)Diagnostic criteria for primary osteoporosis: year 2012 revision J Bone Miner Metab 31 247-e264

[7] Kishimoto H(2020)Bone mineral density after transitioning from denosumab to alendronate J Clin Endocrinol Metab 105 e255-446

[8] Ito M(2014)Once-weekly teriparatide reduces the risk of vertebral fracture in patients with various fracture risks: subgroup analysis of the Teriparatide Once-Weekly Efficacy Research (TOWER) trial J Bone Miner Metab 32 441-140

[9] Yoshikawa H(2019)Bone mineral density response rates are greater in patients treated with abaloparatide compared with those treated with placebo or teriparatide: results from the ACTIVE phase 3 trial Bone 120 137-312

[10] Kishida M(2012)Responder analysis of the effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer Prostate Cancer Prostatic Dis 15 308-205